Galenica Ltd.

Latest Results (29.04.2026):

Galenica Ltd., Q4 2024 (Annual Report 2024) — Summary: Galenica’s 2024 results (reporting period 1 Jan–31 Dec 2024) show continued growth: consolidated net sales CHF 3,921.1 million (+4.7% vs 2023), adjusted EBIT CHF 211.0 million (+10.3%), and adjusted profit from continuing operations CHF 183.2 million (+13.4%). The Board proposes a CHF 2.30 gross dividend per share (up 4.5%). The Group reports strengthened market positions across pharmacies, wholesale and services while maintaining a solid balance sheet (equity ratio 50.5%).

Top-line and profitability

Net sales: CHF 3,921.1m (+4.7%). Adjusted EBIT: CHF 211.0m (+10.3%); reported EBIT: CHF 214.4m (+7.6%). Adjusted profit from continuing operations: CHF 183.2m (+13.4%).

Dividend and shareholder metrics

Board proposes gross dividend CHF 2.30/share (increase of 4.5%). Earnings per share from continuing operations: CHF 3.67; adjusted EPS: CHF 3.66. Share price at year-end: CHF 74.35; market cap ~CHF 3,704.6m.

Segment performance

Products & Care net sales CHF 1,700.2m (+3.9%), adjusted EBIT CHF 157.3m. Logistics & IT net sales CHF 3,241.4m (+5.3%), adjusted EBIT CHF 56.8m (strong YoY margin improvement).

Operational highlights

Pharmacy network expansion: 12 acquisitions, 2 openings, 4 closures/mergers; organic pharmacy growth +2.7%. Customers used ~193,000 consultations/services (+39% YoY). HCI Solutions performed ~369 million CDS checks (+33%), supporting patient safety.

Cash flow, investments and leverage

Cash flow from operating activities (adjusted): CHF 212.1m (+22.3%). Free cash flow: CHF 61.0m. Net debt (adjusted): CHF 424.1m; equity ratio 50.5%; gearing adjusted ~27.0%.

Sustainability and digitalisation

Report integrates TCFD recommendations for first time. Progress noted on sustainability (e.g., Ecovadis label for Alloga), digital services rollout (Consultation plus, Documedis® CDS checks) and Data & AI governance.

Outlook and strategic initiatives

Management reiterates focus on integrated healthcare network, selective growth, digitalisation, and improving reimbursement for pharmacy services. Planned ERP and warehouse improvements (Galexis) and further rollout of Consultation plus and home-care solutions into 2025.